New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
06:09 EDTVRTX, LULUStocks with implied volatility below IV index mean; LULU VRTX
Stocks with implied volatility below IV index mean; lululemon (LULU) 31, Vertex (VRTX) 41.
News For LULU;VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
08:02 EDTLULUlululemon checks positive, says Bernstein
Subscribe for More Information
06:22 EDTLULUNew Balance to enter 'athleisure' sector, Business Insider reports
New Balance is launching a new "athleisure" line and is planning to mail a catalog to more than 1M U.S. women, Business Insider reports, citing comments from Norma Delaney, head of global marketing for NB Women. The line will compete with offerings from Lululemon (LULU), Under Armour (UA), Victoria's Secret (LB) and Dick's Sporting Goods (DKS). Reference Link
August 28, 2015
07:12 EDTLULUWilliam Blair names 21 stocks best positioned for volatile markets
Subscribe for More Information
August 27, 2015
07:56 EDTLULULululemon September weekly volatility elevated into Q2 and outlook
Lululemon 9/11/15 weekly call option implied volatility is at 66, September is at 61, October is at 48; compared to its 52-week range of 25 to 63, suggesting large near term price movement into the expected release of Q2 results on September 10.
07:52 EDTLULUBarclays would be a buyer of lululemon into the Q2 report
Barclays analyst Matt McClintock believes lululemon will report meaningful upside to his 7.7% total comp estimate when it reports Q2 earnings on September 10. Channel checks suggest a strong consumer response to new tops introduced in Q2 with stock outs above 50%, promising Google search activity, and momentum in men's. McClintock believes his earnings estimates will prove conservative and is a buyer into the report. Barclays' rates lululemon an Overweight with an $85 price target on shares.
August 26, 2015
07:09 EDTVRTXVertex, Novavax among select biotechs to buy on weakness, says Piper Jaffray
Subscribe for More Information
August 24, 2015
13:36 EDTVRTXBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use